The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
2.
The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med, 2000; 342:381–389.
3.
The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352:837–853.
4.
BeckRW, ConnorCG, MullenDM, et al.The fallacy of average: How using HbA1c alone to assess glycemic control can be misleading. Diabetes Care, 2017; 40(8):994–999.
5.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
6.
ShahVN, AkturkHK, VigersT, et al.Relationship between daytime versus nighttime continuous glucose monitoring metrics with A1C in adults with Type 1 diabetes. Diabetes Technol Ther, 2023; 25(1):62–68.
7.
FabrisC, HeinemannL, BeckRW, et al.Estimation of hemoglobin A1c from continuous glucose monitoring data in individuals with Type 1 diabetes: Is time in range all we need? Diabetes Technol Ther, 2020; 22(7):501–508.
8.
BeckRW, BergenstalRM, RiddlesworthTD, et al.Validation of time in range as an outcome measures for diabetes clinical trials. Diabetes Care, 2019; 42(3):400–405.
9.
ShahVN, KanapkaLG, AkturkHK, et al.Time in range is associated with incident diabetic retinopathy in adults with Type 1 diabetes: A longitudinal study. Diabetes Technol Ther, 2024; 26(4):246–251.
10.
KovatchevBP, LoboB, FabrisC, et al.The Virtual DCCT: Adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications. Diabetes Technol Ther, 2025; 27(3):209–216; doi: 10.1089/dia.2024.0404
11.
KarakusKE, AkturkHK, AlonsoGT, et al.Association between diabetes technology use and glycemic outcomes in adults with Type 1 diabetes over a decade. Diabetes Care, 2023; 46(9):1646–1651.
12.
Gubitosi-KlugRA, BraffettBH, WhiteNH, et al.; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Risk of severe hypoglycemia in Type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. Diabetes Care, 2017; 40(8):1010–1016.
13.
ShahVN, KerrD. What is a normal glucose value? Lancet Diabetes Endocrinol, 2025; 13(3):172–174.
14.
LoboB, KanapkaL, KovatchevBP, et al.The association of time-in-range and time-in-tight-range with retinopathy progression in the virtual diabetes control and complications trial continuous glucose monitoring dataset. Diabetes Technol Ther, 2025; 27(7):558–561; doi: 10.1089/dia.2025.0033
15.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products; Draft Guidance for Industry. May, 2023. Available from: https://www.fda.gov/media/168475/download [Last accessed: April2, 2025].
16.
BeckRW. The association of time in range and diabetic complications: The evidence is strong. Diabetes Technol Ther, 2023; 25(6):375–377.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
